Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes

Yasuhiro Suzuki,1,4 Akihiro Tomita,1,3 Fumika Nakamura,1,2 Chisako Iriyama,1 Mizuho Shirahata-Adachi,1 Kazuyuki Shimada,1,3 Akimi Akashi,1 Yuichi Ishikawa,1 Norio Kaneda2 and Hitoshi Kiyoi1

1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya; 2Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Nagoya; 3Institute for Advanced Research, Nagoya University, Nagoya, Japan

Key words
Biomarkers, genetic mutations, myelodysplastic syndromes, peripheral blood cell-free DNA, targeted sequencing

Correspondence
Akihiro Tomita, Department of Hematology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan.
Tel: +81-562-93-9242; Fax: +81-562-95-0016; E-mail: atomita@fujita-hu.ac.jp

4Present address: Department of Hematology/Oncology Research, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
5Present address: Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan

Funding Information
National Cancer Center Research and Development Fund (26-A-4); Ministry of Education, Culture, Sports, Science and Technology, Japan (24591388, 15K09473).

Received March 25, 2016; Revised June 13, 2016; Accepted June 17, 2016

Cancer Sci 107 (2016) 1329–1337
doi: 10.1111/cas.12994

Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by peripheral cytopenia, dysplasia and a risk of progression to acute myeloid leukemia (AML). (1) Recently, several somatic mutations in genes that affect DNA methylation (e.g. DNMT3A, TET2 and IDH1/2), chromatin modification (e.g. EZH2 and ASXL1), RNA splicing (e.g. SF3B1, U2AF1, SRSF2 and ZRSR2), cohesion complexes (e.g. STAG2, SMC3 and RAD21) and others (2)–(8) have been identified in more than 90% of MDS patients. (9,10) Some of these genetic abnormalities are closely related to specific phenotypes, such as ring sideroblasts, (6) hypo-lobulated granulocytes (11,12) and micro-megakaryocytes (13) as well as prognosis. (9,10,14) In AML, several specific genetic mutations act as initiating and/or driver mutations and result in disease onset and progression via a growth advantage and clonal expansion of leukemic stem cells. (15–18) Similar molecular mechanisms may also occur in MDS. (19–21) Researchers have speculated that accumulation of specific genetic abnormalities, such as mutations in BCOR, (22) SETBP1, (23) ASXL1, (10) STAG2 and SMC3, (24) may be critical for relapse, progression and acquisition of drug resistance. (25)

Thus, genetic analyses using serially harvested samples at various time points during the clinical course have become more important not only for diagnosis but also for recognizing the disease status and selecting the optimal molecular targeted therapies. Genomic DNA from bone marrow (BM) mononuclear cells (MNC) obtained by BM aspiration is usually used for genetic analyses. However, repeated BM aspirations should be avoided as much as possible because they are difficult for patients.

Recently, peripheral blood circulating cell-free DNA (PBCfDNA), which is fragmented DNA detected in plasma and serum, has received attention as an alternative DNA source that originates from malignant tumors. Utilization of PBCfDNA for genetic analyses has been reported mainly for solid tumors, such as breast, (26–28) colorectal (29) and lung cancer, (30) especially in advanced stage patients. To date, few studies on PBCfDNA in MDS have been published. (31,32) Previously, we...

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
reported the usefulness of PBcfDNA for detecting genetic and epigenetic abnormalities in a limited number of MDS cases. We showed that genetic mutations detected in BM CD34(+)/CD38(−) blast cells accumulate in PBcfDNA and that epigenetic changes after using azacitidine, a DNA methyltransferase inhibitor, can be detected more sensitively in serially harvested PBcfDNA than PBMNC. However, detailed information about the clinical and molecular features of PBcfDNA has not been reported.

In this manuscript, we report the molecular characteristics of PBcfDNA from MDS patients and healthy donors, and the correlation of PBcfDNA with laboratory data and clinical features. We also show that PBcfDNA can be utilized as a biomarker of the disease status and as an alternative source of tumor DNA instead of BMMNC for genetic analyses.

Materials and Methods

Patients' characteristics. After obtaining appropriate informed consent, the study population included 33 patients with MDS-related diseases (MDS; N = 24, MDS/MPN; N = 2, and MDS/ tAML; N = 7) diagnosed at Nagoya University Hospital. Diagnosis and prognostic stratification were assigned according to the World Health Organization classification(33) and International Prognostic Scoring System (IPSS).(34) Patient characteristics are summarized in Table S1.

Collection of plasma, serum and mononuclear cells from peripheral blood. Bone marrow and PB samples were harvested from these patients at or close to the same disease period. In one patient with MDS refractory anemia with excess blasts-2 (RAEB-2) at diagnosis, BM and PB samples were serially collected during the clinical course, and a total of 34 BM and PB paired samples were analyzed. Plasma samples were collected in all 33 patients, and serum samples were harvested from 28 patients. Plasma from 14 healthy volunteer donors was also harvested after obtaining appropriate informed consent. Blood collection tubes with EDTA-2Na were mainly utilized for further use. After centrifugation for 10 min at 4°C, PB cfDNA was extracted using the QIAamp MinElute Virus Vacuum Kit (Qiagen, Valencia, CA, USA). PBcfDNA from plasma (plasma-PBcfDNA) and serum (serum-PBcfDNA) was isolated following 1% agarose gel electrophoresis, and the concentration was measured by using BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA).

Confirmation of PBcfDNA concentration. Plasma-/serum-PBcfDNA concentrations (ng/mL of plasma or serum) were stratified into lower (low and intermediate-1) and higher (intermediate-2 and high) IPSS scores, respectively. All mutations were determined to be somatic mutations following comparison with the corresponding germline control DNA. The PCR primers utilized are shown in Table S2. Targeted sequencing was performed for two patients (UPN #2 and #33) using the TruSight Myeloid Sequencing Panel (Illumina, San Diego, CA, USA). Detection of FLT3 internal tandem duplication (FLT3-ITD) by PCR was carried out as reported previously.(37)

Statistical analyses. Statistical analysis with the unpaired t-test and nonlinear regression were performed with Prism version 5 software (Graph Pad Software, La Jolla, CA, USA). P-values < 0.05 were considered statistically significant.

Results

Characteristics of PBcfDNA in myelodysplastic syndromes and healthy donors. To determine the characteristics of PBcfDNA in MDS, plasma-/serum-PBcfDNA from a clinically well-characterized cohort of MDS patients was analyzed by agarose gel electrophoresis, and the concentration was measured by using gel imaging software. All plasma-PBcfDNA (MDS: N = 34, healthy donors; N = 14) and serum-PBcfDNA (MDS: N = 29) samples were successfully visualized in 1% agarose gels (Fig. S1a). As indicated previously,(31) PBcfDNA was detected as a ladder pattern of 160–180 bp following 1% agarose gel electrophoresis and analysis using BioAnalyzer, a capillary electrophoresis system (Fig. S1b). Considering the fragmented size of PBcfDNA, PBcfDNA may exist in nucleosomal structures. The red arrows in Figure S1(a) may correspond to DNA fragments from mono-nucleosomes to penta-nucleosomes. Note that large variations in PBcfDNA concentrations were detected among patients (Fig. S1a).

Comparison of the PBcfDNA concentrations from plasma and serum. PBcfDNA concentrations (ng/mL of plasma or serum) are depicted in Figure 1(a). The median plasma-PBcfDNA and serum-PBcfDNA concentrations were 60.7 ng/mL (range: 0–915.9) and 30.7 ng/mL (range: 0–465.2), respectively. The plasma-/serum-PBcfDNA concentration from MDS patients was significantly higher than the plasma-PBcfDNA concentration from healthy donors (P = 0.041 and 0.048, respectively). The plasma-PBcfDNA and serum-PBcfDNA concentrations were significantly correlated (r = 0.892, P < 0.0001) (Fig. 1b).

The PBcfDNA concentration is significantly higher in higher-risk International Prognostic Scoring System patients than in lower-risk International Prognostic Scoring System patients. International Prognostic Scoring System scores(34) in this cohort are shown in Table S1. Of the 33 MDS patients, 14 and 12 cases were stratified into lower (low and intermediate-1) and higher (intermediate-2 and high) IPSS scores, respectively. Seven cases showed transformation to secondary AML at the time of
PB sample collection. The concentrations of plasma-PBcfDNA were significantly higher in the higher-risk IPSS score group compared to the lower-risk IPSS score group (Fig. 1c, \( P = 0.034 \)). The plasma-PBcfDNA concentration in secondary AML was not significantly higher than that in MDS lower-risk and higher-risk IPSS groups (\( P = 0.069 \) and \( P = 0.61 \), respectively). The concentrations of serum-PBcfDNA from the lower-risk and higher-risk IPSS groups were not significantly different (\( P = 0.121 \)) (data not shown).

**Correlation of PBcfDNA concentration with laboratory data.** To determine the biochemical characteristics of PBcfDNA, we compared the PBcfDNA concentrations with laboratory data (Fig. 2). The plasma-PBcfDNA and serum-PBcfDNA concentrations were significantly correlated with the serum lactate dehydrogenase (LDH) level (plasma: \( P < 0.0001 \), serum: \( P < 0.0001 \)) and the PB blast count (plasma: \( P = 0.034 \), serum: \( P = 0.025 \)). However, we found no significant correlations between the PBcfDNA concentration and the following PB laboratory data: C-reactive protein (CRP) (plasma: \( P = 0.994 \), serum: \( P = 0.477 \)), white blood cell counts (WBC) (plasma: \( P = 0.465 \), serum: \( P = 0.498 \)), and hemoglobin (Hb) (plasma: \( P = 0.651 \), serum: \( P = 0.956 \)). We also found no correlation between the PBcfDNA concentration and the following laboratory data using BM samples: BM cell count (plasma: \( P = 0.248 \), serum: \( P = 0.281 \)), BM blast percentage (plasma: \( P = 0.947 \), serum: \( P = 0.731 \)) and BM blast count (plasma: \( P = 0.551 \), serum: \( P = 0.817 \)). These data suggest that the PBcfDNA originates from MDS clones that were likely more fragile than normal blood cells, and the PBcfDNA concentration may be correlated with the disease status and reflects the LDH level and PB blast cell counts, as well as IPSS risk stratification.

If the fragility of MDS clones is closely related to the PBcfDNA concentration, the strategy for sample preparation in laboratories is quite critical. To investigate the possibility that genomic DNA may be released from MDS clones in sample tubes after sample collection and storage in refrigerators, plasma from whole blood samples of a patient that had been stored in a refrigerator for different time periods, from 15 min to 24 h after blood collection, was prepared, and then PBcfDNA extraction was performed. No significant elevation of PBcfDNA concentration was observed in this case, even
after preservation for 24 h in a refrigerator (Fig. S2). These data suggest that the PBcfDNA concentration may depend on ineffective hematopoiesis resulting from increasing apoptosis in a patient’s body rather than release from cells in sample collection tubes.

**PCR amplification using PBcfDNA for Sanger sequencing.** For mutation analyses using the Sanger sequencing strategy, we first optimized the PCR, because genomic DNA in PBcfDNA is fragmented and is quite different from total genomic DNA extracted from whole cells. Two different primer pairs were used to amplify *U2AF1* exon 2, resulting in PCR products of different sizes (primer set (i)): 324 bp and (ii): 161 bp (Fig. 3a). When using BM-DNA, the PCR amplification efficacy was similar between primer sets (i) and (ii) (Fig. 3b; BM-DNA), even when using a lower concentration (0.2 ng) of template DNA. When using PBcfDNA as a PCR template, the amplification efficacy was significantly higher when using primer set b) than a) (Fig. 3b; PBcfDNA). The difference was

---

**Fig. 2.** Correlation of the plasma-PBcfDNA and serum-PBcfDNA concentration with laboratory data. Correlation of the plasma-PBcfDNA and serum-PBcfDNA concentrations with laboratory data was analyzed. (a) Serum lactate dehydrogenase (LDH), (b) C-reactive protein (CRP), (c) white blood cell counts (WBC), (d) hemoglobin (Hb), (e) peripheral blood (PB) blast count, (f) bone marrow (BM) cell count, (g) BM blast percentage and (h) BM blast count. The PBcfDNA concentration was significantly correlated with the LDH level and the PB blast count. The *P*-value was confirmed in linear regression analysis, and the asterisks indicate significant data. Black circles, plasma-PBcfDNA; white squares, serum-PBcfDNA.
obvious when using a lower concentration (1 ng or less). Considering these data, we designed all primer sets to amplify approximately 160 bp for Sanger sequencing of the target genes (Table S2).

Detection of genetic mutations with Sanger sequencing and targeted sequencing strategies in BM-DNA and PBcfDNA. To confirm whether the genetic mutations detected in BM-DNA are also detectable in PBcfDNA, Sanger sequencing was performed to detect exons of IDH2, U2AF1 and SETBP1 using BM-DNA for all samples. For 2 patients (UPN #2 and #6) that showed 4q uniparental disomy in SNP array analysis, TET2 mutation was analyzed with Sanger sequencing. The FLT3-ITD mutation was also analyzed by PCR using BM-DNA for all samples. In patients in whom some genetic mutations were detected in BM-DNA, genetic mutations were also analyzed in PBcfDNA. Targeted sequencing, a next-generation sequencing strategy, was performed in two patients (UPN #2 and #33) using both BM-DNA and PBcfDNA, and the concordance was confirmed.

The genetic mutations detected in BM-DNA and PBcfDNA from the 33 MDS patients are summarized in Table 1. Almost all genetic mutations detected by Sanger and targeted sequencing were also detectable in plasma-PBcfDNA, Sanger sequencing was performed using (i) and (ii). BM-DNA and plasma-PBcfDNA were analyzed with Sanger sequencing. The FLT3-ITD mutation in PBcfDNA, genetic mutations were also analyzed in PBcfDNA. Targeted sequencing, a next-generation sequencing strategy, was performed in two patients (UPN #2 and #33) using both BM-DNA and PBcfDNA, and the concordance was confirmed.

The genetic mutations detected in BM-DNA and PBcfDNA were from the 33 MDS patients are summarized in Table 1. Almost all genetic mutations detected by Sanger and targeted sequencing were also detectable in plasma-PBcfDNA. Representative data from Sanger sequencing are shown in Figure S3. In one case (UPN #7), a guanine (G) to cytosine (C) mutation resulting in an R140Q substitution in IDH2 was detected in BM-DNA and three serially harvested plasma-PBcfDNA samples, but was not detected in serum-PBcfDNA (Table 1 and Fig. S4). FLT3-ITD was detected in one patient (UPN #7) in BM-DNA, but was not detected in plasma-/serum-PBcfDNA in the same patient (PCR data not shown). These data suggest that most genetic mutations detected in BM-DNA are also detectable in plasma-/serum-PBcfDNA, and that plasma-PBcfDNA may be more suitable for mutational analysis than serum-PBcfDNA. To detect FLT-ITD in PBcfDNA, optimization of the PCR conditions may be necessary because of the larger size (>180 bp) of the PCR product.

Utilization of serially harvested PBcfDNA to detect disease status. To determine the usefulness of PBcfDNA for confirming disease status, such as disease progression and/or remission, PBcfDNA was harvested serially from several patients. The clinical course of a representative patient is shown in Figure 4.

Discussion

For quantification of PBcfDNA, we performed agarose gel electrophoresis followed by semi-quantification with gel imaging software. We also used BioAnalyzer (Agilent Technologies), which is a capillary electrophoresis system, and NanoVue (GE Healthcare), which is a micro-volume UV-Vis spectrophotometer. The lower limits of sensitivity are 2 and 0.1 ng/μL, respectively, according to the manufacturers’ instructions. Unexpectedly, these two strategies were not useful for accurately detecting the DNA, probably because of the low concentration and/or fragmentation of DNA. Agarose gel electrophoresis followed by quantification using imaging software is a conventional strategy for confirming the concentration and DNA fragmentation pattern, even with low concentrations. However, it takes time, and the background is sometimes problematic. Further improvement of strategies for measuring the DNA concentration is still needed.

The PBcfDNA concentration varied among the MDS patients (Figs 1a,S1a) and, importantly, the concentration was significantly lower in healthy donors. The PBcfDNA concentration was significantly correlated with the serum LDH level and the PB blast count (Fig. 2a,e), and was significantly higher in the higher-risk IPSS score group than in the lower-risk IPSS score group (Fig. 1c). Furthermore, the PBcfDNA concentration in serially harvested samples at different time points of the disease status in a patient appeared to be closely related to disease progression and/or regression (Fig. 4a-c). Importantly, MDS-specific genetic mutations seen in BM cells were also confirmed in PBcfDNA. Our previous data indicated that the
The ratio of the mutated allele in BM CD34(+)CD38(-) blast cells is much higher than that in CD34(+)CD38(+) and CD34(-) cells, and the mutant ratio in PBcfdNA was almost equivalent to or much higher than that in CD34(+)CD38(-) cells. These data strongly suggest that PBcfdNA is mainly derived from MDS clones rather than normal clones and normal tissue. This phenomenon may suggest that genomic DNA release occurs much more readily from MDS clones than from normal hematologic cells. MDS clones are more fragile in the patients’ bodies than normal clones due to ineffective

### Table 1. Comparison of genetic mutations detected in BMDNA and PBcfdNA

| UPN # | DNA source | PBcfdNA amount for sequencing | TET2 | IDH2 | SETBP1 | U2AF1 | SRSF2 | NRAS | TPS3 | FLT3 |
|-------|------------|-------------------------------|------|------|--------|--------|-------|------|------|------|
| 1     | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 2-1   | BM         |                               |       |       |        |        |       |       |       |       |
|       | Plasma     | 1 ng                          |       |       |        |        |       |       |       |       |
|       | Serum      | 1 ng                          |       |       |        |        |       |       |       |       |
| 2-2   | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Plasma     | 50 ng†                        |       |       |        |        |       |       |       |       |
|       | Serum      | 1 ng                          |       |       |        |        |       |       |       |       |
| 3     | BM         |                               |       |       |        |        |       |       |       |       |
|       | Plasma     | 1 ng                          |       |       |        |        |       |       |       |       |
|       | Serum      | 1 ng                          |       |       |        |        |       |       |       |       |
| 4     | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 5     | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 6     | BM         |                               |       |       |        |        |       |       |       |       |
|       | Plasma     | 1 ng                          |       |       |        |        |       |       |       |       |
|       | Serum      | 1 ng                          |       |       |        |        |       |       |       |       |
| 7     | BM         |                               | R140Q| WT   | WT     | WT     | WT    | WT   | WT   | ITD  |
|       | Plasma‡    | 0.0 ng‡                       |       |       |        |        |       |       |       |       |
|       | Plasma§    | 0.0 ng‡                       |       |       |        |        |       |       |       |       |
|       | Plasma¶    | 0.0 ng‡                       |       |       |        |        |       |       |       |       |
|       | Serum      | 1 ng                          |       |       |        |        |       |       |       |       |
| 8     | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 9     | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 10    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 11    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 12    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 13    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Plasma     | 1 ng                          | R140Q| WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Serum      | 1 ng                          | R140Q| WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 14    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 15    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 16    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 17    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 18    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 19    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Plasma     | 0.0 ng†                       | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Serum      | 0.0 ng†                       | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 20    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 21    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 22    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 23    | BM         |                               | R140Q| WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Plasma     | 0.0 ng†                       |       |       |        |        |       |       |       |       |
|       | Serum      | 0.0 ng†                       |       |       |        |        |       |       |       |       |
| 24    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 25    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 26    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 27    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 28    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 29    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 30    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 31    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 32    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
| 33    | BM         |                               | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Plasma     | 50 ng§                        | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |
|       | Serum      | 50 ng§                        | WT   | WT   | WT     | WT     | WT    | WT   | WT   | WT   |

†Harvested at diagnosis as indicated in Figure 4(a). †Harvested just before cord blood transplantation without obtaining remission, as indicated in Figure 4(a). ‡Serially harvested samples during disease progression. ¶Analyzed in targeted sequencing method. ††DNA concentration was below the lower limitation in agarose gel electrophoresis method. ‡‡Band for the tandem duplication was not amplified correctly. KDM6A T726K, GATA2 A164T, STAG2 CS27F detected in both BM-DNA and PBcfdNA samples were determined as single nuclear polymorphisms (SNP). BM, bone marrow; plasma, PBcfdNA from plasma; serum, PBcfdNA from serum; WT, wild type; § detected mutations; ‡ not analyzed.
hematopoiesis, aberrant membrane structure, and accelerated apoptosis. (34)

In contrast, the plasma-PBcfDNA concentration in secondary AML was significantly higher than that in normal controls, but was not significantly higher than that in lower-risk and higher-risk MDS patients. This phenomenon suggests that the DNA release from tumor cells in secondary AML cannot be estimated simply by PB blast cell count but that fragility also impacts DNA release. Further accumulation of patients and detailed analyses of the backgrounds of secondary AML in each patient may be required.

The serum-PBcfDNA concentration tended to be lower compared to plasma-PBcfDNA (Fig. 1a), and the difference in concentration between lower-risk and higher-risk MDS patients was not significant when using serum-PBcfDNA (data not shown). One possible reason for this phenomenon is that a significant amount of PBcfDNA can be trapped in blood clots, decreasing the precision for determination of the PBcfDNA concentration.

An SNP in CDKN2A (Fig. 4d), which was confirmed in recipient PBcfDNA before CBT, was not detected in PBcfDNA after CBT with CR. This finding suggests that a large proportion of PBcfDNA in a healthy person originates from blood cells, rather than from other tissues such as the liver, intestine and others. Moreover, the PBcfDNA concentration was still high in the condition of CR after CBT, as shown in Figure 4(a). This phenomenon indicated that the PBcfDNA concentration may not reflect only the pathologic state but also certain aspects of the physiological state such as proliferation of hematopoietic cells after engraftment following stem cell transplantation. Further accumulation of samples from patients who have undergone stem cell transplantation is also required to investigate this possibility.

As shown in Figure 2(f-h), we found no correlations between the PBcfDNA concentration and BM data, including BM cell count, BM blast percentage and BM blast count. As we experienced in the clinical setting, results of BM aspiration, such as cellularity and density, are sometimes different according to the location of BM aspiration and because the aspiration skills may not be the same for all clinicians. Furthermore, the definition of BM blast cells, especially in MDS, is sometimes difficult because of the variety of dysplasia and the regional heterogeneity of genetic abnormalities in MDS clones. (15,21) However, PB collection is usually much easier than BM aspiration, and PB is likely more homogeneous regardless of the collection site. Our data and speculation about sample collection suggest that PBcfDNA may be much more accurate for detection of genetic abnormalities that exist in a patient’s entire hematopoietic cell population than BM-DNA if a high enough DNA concentration for sequencing can be obtained from PBcfDNA.

Analyses using serially harvested PBcfDNA samples from a patient who was treated with 5-Aza followed by CBT indicated that the DNA concentration was markedly elevated (63.1–688.6 ng/mL) at the time of disease progression as defined by the clinical findings of documented tumor fever and LDH elevation. The ratio of the U2AF1 mutated allele in plasma-PBcfDNA was also increased (Fig. 4a,b), probably due to significant expansion of MDS clones in his entire body. These data suggest that the PBcfDNA concentration and the ratio of the mutated allele can be utilized as biomarkers to predict the disease status and confirm minimal residual disease.

We tried to perform pyro-sequencing analysis to quantitate the U2AF1 mutation, but, unfortunately, the assay was not successful. Inappropriate assay conditions probably related to fragmentation of the template DNA may explain this lack of success. Further improvement of the assay system and/or introducing allele-specific quantitative PCR are required.

Because PBcfDNA showed a fragmented pattern that likely reflects nucleosomal structures, we optimized the PCR conditions for Sanger sequencing with primer sets that amplified approximately 160-bp DNA products (Fig. 3). Most of the genetic mutations were confirmed by Sanger sequencing after obtaining specific PCR products (Table 1). However, to detect FLT3-ITD, PCR amplification using previously reported primer sets did not work well (data not shown, Table 1), probably because the size of the PCR products was >200 bp. (38) We tried to design PCR primers on the flanking position of the...
duplicated sequences, but this was quite difficult because the duplicated sequences are sometimes longer than 200 bp, and also because the duplicated sequences vary from patient to patient. Further improvement of the detection strategy for FLT3-ITD using PBcfDNA is required.

PBcfDNA can be obtained from both plasma and serum,(31,39–41) but which sample is more suitable for detecting genetic abnormalities in malignant situations, especially MDS, was unclear. In healthy individuals, the concentration of serum-PBcfDNA tended to be higher than that of plasma-PBcfDNA.31,39 In our experiment, the concentration of plasma-PBcfDNA in MDS tended to be higher than that of serum-PBcfDNA, but the difference was not significant (Fig. 1a). Our previous limited data for genetic analyses using PBcfDNA indicate that both plasma-PBcfDNA and serum-PBcfDNA can be utilized for Sanger sequencing, and the mutant allele frequencies in plasma-PBcfDNA and serum-PBcfDNA are almost the same and relatively higher compared with the frequency in DNA from BM CD34(+)/38(−) blast fraction cells.31 Mohamedali et al.32 report that serum-PBcfDNA can be utilized for Sanger sequencing in some cases. However, the concordance with BM-DNA was only 42%, and Sanger sequencing could be performed in only 9 (75%) of 12 cases. In our experiment, a genetic mutation in IDH2 that was confirmed in BM-DNA and plasma-PBcfDNA was not detected in serum-PBcfDNA in one case (Table 1 and Fig. S4). Furthermore, Board et al.39 report that the serum-PBcfDNA concentration increases in a time-dependent manner after blood coagulation, suggesting release of genomic DNA from white blood cells containing normal clones. This phenomenon may be a reasonable explanation for the increasing contamination with the wild-type genome in serum-PBcfDNA. Thus, plasma-PBcfDNA may be more suitable for genetic analysis in MDS than serum-PBcfDNA.

Our data strongly suggest that PBcfDNA is a useful alternative source of tumor DNA in MDS, not only for conventional sequencing strategies but also for newer, comprehensive genetic analysis. Collection of PB is much safer, easier and relatively less painful compared to BM aspiration, and serial sample collection is also feasible. Furthermore, storing plasma/serum samples in the clinical setting is much easier and faster than storing PBMNC and BMMNC. PBcfDNA may also become a useful biomarker that closely reflects the patient’s clinical situation. Further optimization and improvement of the sensitivity of sequencing analyses is still required for this strategy to be widely utilized in the clinical setting, especially for patients with a low PBcfDNA concentration.

**Acknowledgments**

This work was supported in part by Grants-in-Aid from the National Cancer Center Research and Development Fund (26-A-4), and the Ministry of Education, Culture, Sports, Science and Technology (24591388, 15K09473), Japan. We thank Dr Seishi Ogawa and Dr Masashi Sanada for performing the SNP array analysis. We thank Chika Wakamatsu, Yoko Matsuyama, Yukie Konishi, Manami Kira, Rie Kojima, Yuko Kojima, Emi Kono and Saya Kojima for valuable laboratory assistance.
Disclosure Statement

H. K. received research funding from Bristol-Myers Squibb, Chugai Pharmaceutical, Kyowa Hakko Kirin, Dainippon Sumitomo Pharma, and Daiichi Sankyo. The other authors have no relevant conflicts to disclose.

References

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–85.
2. Sanada M, Suzuki T, Shih LY et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904–8.
3. Makishima H, Cazzola M, Szaporka H et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myelodysplastic syndromes. J Clin Oncol 2009; 27: 6109–16.
4. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29: 504–15.
5. Yoshida K, Sanada M, Shiraishi Y et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64–9.
6. Makishima H, Visconte V, Sakaguchi H et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203–10.
7. Yamazaki J, Issa JP. Epigenetic aspects of MDS and its molecular targeted therapy. Int J Hematol 2013; 97: 155–62.
8. Kon A, Shih LY, Minamino M et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232–7.
9. Haferlach T, Nagata Y, Grossmann V et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–7.
10. Bejar R, Lord A, Stevenson KE et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124: 2705–12.
11. Muto T, Sashida G, Oshima M et al. Concurrent loss of Ehz2 and Tert2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210: 2627–39.
12. Kim E, Ilagan JO, Liang Y et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 2015; 27: 617–30.
13. Schneider RK, Adema V, Heckl D et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 2014; 26: 509–20.
14. Bejar R, Stevenson KE, Caughey BA et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376–82.
15. Welsh JS, Ley TJ, Link DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264–78.
16. The Cancer Genome Atlas Research Network., Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–74.
17. Kihara R, Nagata Y, Kiyoi H et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014; 28: 1586–95.
18. Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol 2013; 97: 165–74.
19. Walter MJ, Shen D, Shao J et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275–82.
20. Papaemmanuail E, Gerstung M, Malcovati L et al. Clinical, biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616–27; quiz 99.
21. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013; 122: 4021–34.
22. Damm F, Chesnais V, Nagata Y et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013; 122: 3169–77.
23. Makishima H, Yoshida K, Nguyen N et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45: 942–6.
24. Thota S, Viny AD. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 2014; 124: 1790–9.
25. Xie M, Lu C, Wang J et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472–8.
26. Murtaza M, Dawson SJ, Tsai DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108–12.
27. Dawson SJ, Tsai DW, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 366: 1199–209.
28. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res 2013; 15: 211.
29. Thiery AR, Moulle F, El Messaoudi S et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014; 20: 430–5.
30. Wang S, An T, Wang J et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced nonsmall cell lung cancer. Clin Cancer Res 2010; 16: 1324–30.
31. Iriyama C, Tomita A, Hoshino H et al. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Biochem Biophys Res Commun 2012; 419: 662–9.
32. Mohamedali AM, Alkhatabi H, Kulasekararaj A et al. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood 2013; 122: 567–70.
33. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC: Lyon, 2008.
34. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–88.
35. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML–RARα are critical for the lack of responsiveness to arsenic trioxide treatment. Blood 2011; 118: 1600–9.
36. Watanabe K, Terakawa S, Martens AC et al. Target antigen density governs the efficacy of anti-cd20-cd28-cd3 zeta chimeric antigen receptor-modified effector CD8+ T Cells. J Immunol 2015; 194: 911–20.
37. Kiyoi H, Tawatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333–7.
38. Kiyoi H, Naoe T, Yokota S et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 447–52.
39. Board RE, Williams VS, Knight L et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci 2008; 1137: 98–107.
40. Morgan SR, Whiteley J, Donald E et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol 2012; 5: 15–22.
41. Elshimaiti YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 2013; 14: 18925–58.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Figure S1. Confirmation of the fragmentation pattern of plasma/serum-PBcfdNA in agarose gel electrophoresis.

Figure S2. The difference of PBcfdNA concentration in peripheral blood samples harvested at the different time points.

Figure S3. Detection of genetic mutations in PBcfdNA.

Figure S4. Detection of IDH2 mutation using plasma/serum-PBcfdNA in UPN #7.

Table S1. Patients’ characteristics.

Table S2. PCR primers.